Drugs / Tribendimidine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07074444 | Jul 2025 → Nov 2026 expected | clonorchiasis | First Affiliated Hospital of Guangxi Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tribendimidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07074444 ↗ |
| Modality | Small molecule | — CHEMBL427256 ↗ |
| Route | Oral | “Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.” NCT07074444 ↗ |